FinscoFinsco

Collegium Pharmaceutical (US.COLL)

Capital Allocation Audit · Period: 2013 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.COLL · YoY: 2026 Q1 vs 2025 Q1

MetricValueYoY
FCF Conversion99.5%→
ROE4.6%↑
Cash Conversion394.0%↓
D/E Ratio2.59↑
Gross Margin60.6%↑
US.COLL (Collegium Pharmaceutical) | YoY: 2026 Q1 vs 2025 Q1


Metric            Value  YoY
----------------------------
FCF Conversion    99.5%    →
ROE                4.6%    ↑
Cash Conversion  394.0%    ↓
D/E Ratio          2.59    ↑
Gross Margin      60.6%    ↑
Key Metrics
US.COLL (Collegium Pharmaceutical) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY
----------------------------
FCF Conversion 99.5% →
ROE 4.6% ↑
Cash Conversion 394.0% ↓
D/E Ratio 2.59 ↑
Gross Margin 60.6% ↑

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies